New Path Molecular Research

New Path Molecular is going Beyond ADCs. We us cutting edge chemistry techniques to develop novel, fully synthetic drug conjugates for pan-tumour biomarkers which address the limitations of conventional Antibody Drug Conjugates. Our first indications are pancreatic and colorectal cancer.